201 results on '"Doolman, Ram"'
Search Results
2. Author Correction: Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
3. Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up
4. Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study
5. Superior immunogenicity and effectiveness of the third compared to the second BNT162b2 vaccine dose
6. Maternal-neonatal transfer of SARS-CoV-2 immunoglobulin G antibodies among parturient women treated with BNT162b2 messenger RNA vaccine during pregnancy
7. Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
8. Humoral response superiority of the monovalent XBB.1.5 over the bivalent BA.1 and BA.5 mRNA COVID-19 vaccines
9. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers
10. Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel
11. Multi-center nationwide comparison of seven serology assays reveals a SARS-CoV-2 non-responding seronegative subpopulation
12. Low FXIII activity levels in intensive care unit hospitalized COVID-19 patients
13. Corrigendum to 'Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up', Clinical Microbiology and Infection Volume 29, Issue 7, July 2023, Pages 918-923
14. Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines
15. Corrigendum to “Immunogenicity of Omicron BA.1-adapted BNT162b2 vaccines: randomized trial, 3-month follow-up” [Clin Microbiol Infect] 29 (7) (2023) 918–923
16. Factors Associated With Protection From SARS-CoV-2 Omicron Variant Infection and Disease Among Vaccinated Health Care Workers in Israel
17. Klotho response to treatment with growth hormone and the role of IGF-I as a mediator
18. Reduced Neutralization Efficacy against Omicron Variant after Third Boost of BNT162b2 Vaccine among Liver Transplant Recipients
19. High Immune Response Rate to the Fourth Boost of the BNT162b2 Vaccine against the Omicron Variants of Concern among Liver Transplant Recipients
20. Humoral Response to the Fourth BNT162b2 Vaccination and Link Between the Fourth Dose, Omicron Infection, and Disease Severity in Renal Transplant Recipients
21. Six-Month Follow-up after a Fourth BNT162b2 Vaccine Dose
22. Maternal and Neonatal Immune Responses Following COVID-19 Infection and Vaccinations in Pregnancy
23. The Association Between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection
24. Cellular and humoral response to the fourth BNT162b2 mRNA COVID‐19 vaccine dose in patients with CLL
25. Association between Thrombin Generation and Clinical Characteristics in COVID-19 Patients
26. Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022
27. Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection
28. Early Adverse Events and Immune Response Following Second and Third COVID-19 Vaccination in Pregnancy
29. Immune Response and Clinical Outcomes of BNT162b2 and mRNA1273 Fourth Dose COVID-19 Vaccines; Three Months Follow-up
30. Correlation between Adverse Events and Antibody Titers among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19 Vaccine
31. Reduced neutralization efficacy against SARS-CoV-2 Omicron variant after third boost of mRNA BNT162 vaccine among liver transplant recipients
32. Durability of the immune response to a third BNT162b2 dose; five months follow-up
33. The Predictive Value of Serum ACE2 and TMPRSS2 Concentrations in Patients with COVID-19—A Prospective Pilot Study
34. Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron
35. miR-155: A Potential Biomarker for Predicting Mortality in COVID-19 Patients
36. 4th Dose COVID mRNA Vaccines’ Immunogenicity & Efficacy Against Omicron VOC
37. Correlates of Protection of BNT162b2 Against COVID-19 Infection and Intensity of Symptomatic Disease; the Israeli COVID-19 Family Study (ICoFS)
38. Association between Thrombin Generation and Clinical Characteristics in COVID-19 Patients.
39. Cellular and humoral response to the fourth BNT162b2 mRNA COVID‐19 vaccine dose in patients with CLL.
40. Presence of SARS-CoV-2 antibodies in lactating women and their infants following BNT162b2 messenger RNA vaccine
41. Superior immunogenicity and effectiveness of the 3rd BNT162b2 vaccine dose
42. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
43. Early Immunogenicity and Safety of the Third Dose of BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Among Adults Older Than 60 Years: Real-World Experience
44. Vitamin B 6 supplementation in institutionalized elderly / תוספת ויטמין B 6 לקשישים החיים בבית אבות
45. Humoral Response to the Fourth BNT162b2 Vaccination and Link Between the Fourth Dose, Omicron Infection, and Disease Severity in Renal Transplant Recipients
46. Potential antigenic cross-reactivity between SARS-CoV-2 and Dengue viruses
47. The Association Between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
48. Alendronate for osteoporosis in men with androgen-repleted hypogonadism
49. Decreased Infectivity Following BNT162b2 Vaccination
50. Potential Antigenic Cross-reactivity Between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Dengue Viruses
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.